Your browser doesn't support javascript.
loading
Optogenetic technologies in translational cancer research.
Malogolovkin, Alexander; Egorov, Alexander D; Karabelsky, Alexander; Ivanov, Roman A; Verkhusha, Vladislav V.
Afiliación
  • Malogolovkin A; Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354530, Russia; Martsinovsky Institute of Medical Parasitology, Tropical and Vector-borne Diseases, Sechenov First Moscow State Medical University, Moscow 119435, Russia.
  • Egorov AD; Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354530, Russia.
  • Karabelsky A; Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354530, Russia.
  • Ivanov RA; Center for Translational Medicine, Sirius University of Science and Technology, Sochi 354530, Russia.
  • Verkhusha VV; Department of Genetics and Gruss-Lipper Biophotonics Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA; Medicum, Faculty of Medicine, University of Helsinki, Helsinki 00290, Finland. Electronic address: vladislav.verkhusha@einsteinmed.edu.
Biotechnol Adv ; 60: 108005, 2022 11.
Article en En | MEDLINE | ID: mdl-35690273
Gene and cell therapies are widely recognized as future cancer therapeutics but poor controllability limits their clinical applications. Optogenetics, the use of light-controlled proteins to precisely spatiotemporally regulate the activity of genes and cells, opens up new possibilities for cancer treatment. Light of specific wavelength can activate the immune response, oncolytic activity and modulate cell signaling in tumor cells non-invasively, in dosed manner, with tissue confined action and without side effects of conventional therapies. Here, we review optogenetic approaches in cancer research, their clinical potential and challenges of incorporating optogenetics in cancer therapy. We critically discuss beneficial combinations of optogenetic technologies with therapeutic nanobodies, T-cell activation and CAR-T cell approaches, genome editors and oncolytic viruses. We consider viral vectors and nanoparticles for delivering optogenetic payloads and activating light to tumors. Finally, we highlight herein the prospects for integrating optogenetics into immunotherapy as a novel, fast, reversible and safe approach to cancer treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos de Dominio Único / Neoplasias Límite: Humans Idioma: En Revista: Biotechnol Adv Año: 2022 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Anticuerpos de Dominio Único / Neoplasias Límite: Humans Idioma: En Revista: Biotechnol Adv Año: 2022 Tipo del documento: Article País de afiliación: Rusia Pais de publicación: Reino Unido